ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 438 participants.

Also called NCT05070260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 438 participants (enrolled count) (from the registry)
Sponsor
Acticor Biotech (from the registry)
Registry
  • NCT NCT05070260
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05070260. Randomized; triple masking; primary purpose treatment. Start 2021-09-23 (actual); primary completion 2024-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
Acronym
ACTISAVE
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous glenzocimab (ACT017) 1000 mg
Intervention (Drug)
Intravenous Placebo
Lead sponsor
Acticor Biotech (class: industry)

Record details

Record id
cardio:ct-nct05070260
Content hash
a7e0cf7d42b0bc97c25d244125e67b21c8fd4b503bb01d769eab38e244aa6470